胺碘酮联合厄贝沙坦在阵发性房颤患者中的应用效果

Application effect of amiodarone combined with irbesartan in patients with paroxysmal atrial fibrillation

目的分析胺碘酮联合厄贝沙坦在阵发性房颤患者中的应用效果。方法选择2015年11月至2016年11月我院收治的86例阵发性房颤患者作为研究对象,随机分为试验组和对照组,各43例。对照组患者给予胺碘酮治疗,试验组在对照组的基础上联合厄贝沙坦进行治疗,比较两组患者的应用效果。结果治疗9、12个月后,试验组的窦性心律维持率高于对照组(P<0.05)。治疗后6、9、12个月,两组左心房收缩期末内径均优于治疗前,且试验组优于对照组(P<0.05)。两组患者的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论胺碘酮联合厄贝沙坦能够明显提高阵发性房颤患者的窦性心律维持率,抑制左心房扩张,且安全可靠,值得临床推广。

Objective To analyze the effect of amiodarone combined with irbesartan in patients with paroxysmal atrial fibrillation. Methods From November 2015 to November 2016, 86 patients with paroxysmal atrial fibrillation in our hospital were selected as the research objects, and randomly divided into experimental group and control group, with 43 cases in each group. Patients in the control group were treated with amiodarone. Patients in the experimental group were treated with irbesartan on the basis of the control group. The clinical effects were compared between the two groups. Results After 9 and 12 months of treatment, the maintenance rates of sinus rhythm in the experimental group were higher than those in the control group （P〈0.05）. After 6, 9 and 12 months of treatment, the left atrial diameter in both groups were better than those before treatment, and those in the experimental group were obviously better than the control group （P〈0.05）. There was no significant difference in the total incidences of adverse reactions between the two groups （P〉0.05）. Conclusion Amiodarone combined with irbesartan can significantly improve sinus rhythm maintenance rate in patients with paroxysmal atrial fibrillation, inhibit left atrial expansion. It is safe and reliable, which is worthy of clinical promotion.